LNTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LNTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), Lantheus Holdings's share price is $65.635. Lantheus Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.75. Hence, Lantheus Holdings's Price-to-Free-Cash-Flow Ratio for today is 17.51.
The historical rank and industry rank for Lantheus Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Lantheus Holdings's highest Price-to-Free-Cash-Flow Ratio was 906.67. The lowest was 4.21. And the median was 17.56.
Lantheus Holdings's Free Cash Flow per Share for the three months ended in Dec. 2023 was $1.43. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $3.75.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Lantheus Holdings was -1.20% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 271.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 38.10% per year.
During the past 13 years, Lantheus Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 271.20% per year. The lowest was -57.80% per year. And the median was 20.45% per year.
The historical data trend for Lantheus Holdings's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | 14.11 | 187.36 | 46.67 | 13.67 | 16.83 |
Lantheus Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | 13.67 | 16.24 | 23.87 | 18.56 | 16.83 |
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Price-to-Free-Cash-Flow falls into.
Lantheus Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 65.635 | / | 3.748 | |
= | 17.51 |
Lantheus Holdings's Share Price of today is $65.635.
Lantheus Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Lantheus Holdings (NAS:LNTH) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Lantheus Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrea Sabens | officer: Chief Accounting Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Marshall Robert J. Jr. | officer: CFO and Treasurer | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Paul Blanchfield | officer: Chief Commercial Officer | C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862 |
Mary Anne Heino | director, officer: CEO and President | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Daniel Niedzwiecki | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Etienne Montagut | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Sam R Leno | director | C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760 |
Brian A Markison | director | 501 FIFTH STREET, BRISTOL TN 37620 |
Jean-claude Provost | officer: Chief Medical Officer | C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730 |
Julie Mchugh | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Carol Walker | officer: Senior Vice President, Quality | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Ying Vivian Yao | officer: Chief Human Resources Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
John J. Bolla | director | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
From GuruFocus
By Marketwired • 07-20-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocus Research • 10-03-2023
By GuruFocus Research • 12-11-2023
By GuruFocus Research • 12-18-2023
By Marketwired • 09-01-2023
By GuruFocus Research • 12-08-2023
By Stock market mentor Stock market mentor • 02-08-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 08-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.